Company Overview of Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. engages in the development and manufacture of branded and generic pharmaceutical products. It offers generic pharmaceutical products for a range of therapeutic areas; and generic Gatifloxacin Ophthalmic Solution, 0.5% for the treatment of bacterial conjunctivitis. The company also engages in identifying, developing, and marketing prescription drugs for children through distributors in the United States; and manufactures oral and injectable cephalosporin APIs. In addition, it offers oral contraceptives for the prevention of pregnancy in women. Lupin Pharmaceuticals, Inc. was founded in 2003 and is based in Baltimore, Maryland. The company has plants in Mandideep, A...
111 South Calvert Street
Baltimore, MD 21202
Founded in 2003
Key Executives for Lupin Pharmaceuticals, Inc.
Chief Executive Officer and Managing Director
Compensation as of Fiscal Year 2014.
Lupin Pharmaceuticals, Inc. Key Developments
Lupin Pharmaceuticals, Inc. Launches Authorized Generic for Celebrex Capsules
Dec 11 14
Lupin Pharmaceuticals Inc. has launched the authorized generic for G.D. Searle LLC's Celebrex Capsules (Celebrex) 50 mg, 100 mg, 200 mg and 400 mg strengths.
Lupin Pharmaceuticals Launches Generic Ciprofloxacin in US
Jun 16 14
Lupin Pharmaceuticals has announced the US launch of a generic version of Bayer's Cipro (ciprofloxacin). LiveMint, the launch follows the US Food and Drug Authority (FDA)'s approval of Lupin's ciprofloxacin 5g/100ml and 10g/100ml oral suspension generic in the treatment of certain bacterial infections. Lupin has reportedly suggested that it was the first company to file an abbreviated new drug application for a ciprofloxacin generic and is therefore eligible for 180 days of market exclusivity.
Lupin Pharmaceuticals Inc. Receives Final Approval for its Niacin ExtendedRelease Tablets USP from the United States Food and Drug Administration
Mar 21 14
Lupin Pharmaceuticals Inc. has launched its Niacin ExtendedRelease Tablets USP, 500 mg, 750 mg, 1,000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) on March 20, 2014. Lupin's Niacin ExtendedRelease Tablets USP, 500 mg, 750 mg, 1,000 mg strengths are the ABrated generic equivalent of AbbVie Inc.'s Niaspan Tablets 500 mg, 750 mg, 1,000 mg and used with diet to reduce elevated TC, LDLC, Apo B and TG levels, and to increase HDLC in patients with primary hyperlipidemia and mixed dyslipidemia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|